Matrixyl 3000 vs Acetyl Tetrapeptide-5
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7
Matrixyl 3000 is Sederma's follow-up to the original Matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. It is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence.
Also: Eyeseryl, Ac-beta-Ala-His-Ser-His
Acetyl tetrapeptide-5 is a short synthetic peptide sold by Lipotec (now Lubrizol) as Eyeseryl, made for eye creams that target under-eye puffiness. The pitch is that it reduces fluid leaking into the tissue under the eyes. It is a cosmetic ingredient, and nearly all of the human data comes from the company that sells it.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Matrixyl 3000 | Acetyl Tetrapeptide-5 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Both peptides are matrikines, short collagen-derived signals the skin treats as repair instructions. Palmitoyl tripeptide-1 nudges fibroblasts to produce more collagen, elastin and fibronectin, the scaffolding that keeps skin firm. Palmitoyl tetrapeptide-7 works on the other side of the equation by tamping down release of interleukin-6, an inflammatory messenger that climbs with age and quietly accelerates matrix breakdown, which in turn is thought to limit collagen glycation damage. As with the original Matrixyl, the palmitoyl tails are there to ferry these water-loving peptides through the skin barrier. The combined claim is build more, lose less. | The peptide is acetyl-beta-alanine-histidine-serine-histidine. The manufacturer's lab work claims three effects: it reduces vascular permeability (less fluid seeping out of small blood vessels, tested in an endothelial cell model), it inhibits glycation (sugar damage to proteins like collagen), and it has some ACE-inhibiting activity that is linked to fluid balance. All of that is in vitro and company-generated. An important reality check: under-eye bags have several causes, and a lot of them in older adults come from fat pads pushing forward and loose skin, not fluid. A peptide aimed at fluid cannot touch fat-pad bags, so even in the best case it fits morning puffiness better than structural eye bags. |
| Common Dosing | Limited community data available See research protocols | 1% of the Eyeseryl solution in an eye cream Twice daily |
| Administration | Topical (serums, creams) | Topical (eye creams, gels, serums) |
| Typical Duration | Ongoing use for maintained effects | 28-60 days in manufacturer studies; ongoing use to maintain any effect |
| Best Time to Take | Morning or as directed | Morning and evening, gently patted under the eyes |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Matrixyl 3000 has a coherent, biologically reasonable mechanism, and in vitro studies do show its components stimulating fibroblast proliferation and synthesis of collagen types I, III, IV and VII, with the tetrapeptide reducing IL-6. The catch for a careful reader is that most of the supporting clinical work, including the commonly cited 12-week trials reporting reductions in wrinkles and skin laxity, originates from or was sponsored by the manufacturer rather than independent labs, and large published placebo-controlled trials specific to this exact complex are sparse. The strongest truly independent peptide evidence in this family is still the original Pal-KTTKS Matrixyl data. So Matrixyl 3000 is best described as a sensible, well-tolerated upgrade on paper with solid mechanistic and in vitro backing, but with human efficacy that rests heavily on industry sources rather than rigorous third-party trials. It targets collagen and inflammation, not muscle, so expectations should be texture and firmness, not Botox-like smoothing. | We could not find an independent, peer-reviewed clinical trial of acetyl tetrapeptide-5. The evidence is manufacturer data reported in trade publications. Lipotec's best-known study used a 1% Eyeseryl cream on one eye and placebo on the other in male volunteers aged 30 to 65, twice daily for 28 days, and reported about a 30% reduction in under-eye puffiness volume, with most volunteers rating it positively. Another supplier document describes a 60-day study in 20 women using a cream with a very low peptide level, scored from photos by a dermatologist. Other summaries quote different numbers (17% to 21%) from studies we could not trace to an original paper. The studies differ in concentration, sex, length and how puffiness was measured, so they cannot be pooled. Independent ingredient databases rate the evidence as limited for exactly this reason. Bottom line: plausible for mild fluid puffiness, cheap to try in an eye cream, but not a fix for true eye bags and not backed by independent trials. |
Frequently Asked Questions: Matrixyl 3000 vs Acetyl Tetrapeptide-5
What is the difference between Matrixyl 3000 and Acetyl Tetrapeptide-5?
Matrixyl 3000 is a skin & hair peptide that matrixyl 3000 is sederma's follow-up to the original matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (pal-ghk) and palmitoyl tetrapeptide-7 (pal-gqpr). the idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. it is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence. Acetyl Tetrapeptide-5 is a skin & hair peptide that acetyl tetrapeptide-5 is a short synthetic peptide sold by lipotec (now lubrizol) as eyeseryl, made for eye creams that target under-eye puffiness. the pitch is that it reduces fluid leaking into the tissue under the eyes. it is a cosmetic ingredient, and nearly all of the human data comes from the company that sells it. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Matrixyl 3000 or Acetyl Tetrapeptide-5?
Neither is universally "better" - the choice depends on your specific goals. Matrixyl 3000 is typically used for skin & hair purposes, while Acetyl Tetrapeptide-5 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Matrixyl 3000 and Acetyl Tetrapeptide-5 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Matrixyl 3000 and Acetyl Tetrapeptide-5 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.